SOLOIST-WHF Post-HF Benefit Index Calculator

Clinical calculation support · Verify results before clinical use

Clinical input profile

Enter patient values to display the prototype's arithmetic summary.

Research prototype
Important: This is an unvalidated heuristic recreated from the supplied code. It is not a published SOLOIST-WHF score, does not estimate individual treatment benefit, and must not be used to select or withhold therapy.

Clinical context

SOLOIST-WHF studied sotagliflozin, a dual SGLT1/2 inhibitor, in patients with type 2 diabetes and a recent episode of worsening heart failure. The primary endpoint was the total number of cardiovascular deaths, hospitalizations for heart failure, and urgent visits for heart failure.

In the trial, the primary endpoint event rate was 51.0 versus 76.3 events per 100 patient-years with sotagliflozin and placebo, respectively (hazard ratio 0.67; 95% CI 0.52–0.85). This is a trial-level treatment effect, not an individualized estimate generated by this page.

How to use this page

  • Use inputs only to inspect the arithmetic of the supplied prototype.
  • Do not interpret the point total as a validated prognosis or treatment-response score.
  • Use current evidence, guidelines, product labeling, contraindications, and individual assessment for treatment decisions.

Limitations and interpretation

The eight variables, point weights, and cutoffs were specified in the supplied code. The cited SOLOIST-WHF publication does not validate this composite score or its proposed benefit categories.

The trial enrolled a defined population with type 2 diabetes and recent worsening heart failure. Results should not be generalized without considering eligibility, clinical stability, renal function, blood pressure, concomitant treatment, and the relevant therapy's approved indications.

The trial stopped early because of loss of sponsor funding. Its primary endpoint included recurrent events; the reported relative reduction is not equivalent to a reduction in an individual's mortality risk.

References

Bhatt DL, Szarek M, Steg PG, et al.; SOLOIST-WHF Trial Investigators.Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2021;384:117–128. DOI: 10.1056/NEJMoa2030183. PMID: 33200892.
Szarek M, et al.Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure: A Randomized Trial. Ann Intern Med. 2021;174(8):1065–1072. DOI: 10.7326/M21-0651. PMID: 34152828.
Clinical disclaimer: This is an educational software prototype, not a validated clinical decision-support system. Its arithmetic score must not be used to estimate individual treatment benefit, predict outcomes, or determine whether treatment should be started, continued, or withheld.